The Real Cost of Challenging Big Pharma Patents
Pharma IP teams, hedge funds, and biosimilar developers treat a Paragraph IV filing as a legal event. It is not. […]
The Real Cost of Challenging Big Pharma Patents Read Post »
The Repurposing Revolution: Unlocking Hidden Value in Pharmaceutical Patents
Introduction: Beyond Serendipity – The New Strategic Imperative For decades, the pharmaceutical industry has operated on a model of heroic,
The Repurposing Revolution: Unlocking Hidden Value in Pharmaceutical Patents Read Post »
Russia’s $30 Billion Pharma Market: IP Battlegrounds, Patent Cliffs, and the Sovereignty Trap
The Russian pharmaceutical market generated 2.85 trillion roubles in 2024 — but every dollar of that growth evaporated in currency
The $28B CIS Generic Drug Market: IP Strategy, Regulatory Risk, and Biosimilar Opportunity Through 2030
The Commonwealth of Independent States pharmaceutical market is one of the last large generic drug markets where the rules are
Brazil’s $57B Pharma Market: The IP, Patent, and Competitive Intelligence Playbook
Brazil’s pharmaceutical sector has quietly become one of the most strategically interesting IP battlegrounds in the world. The country’s market
Brazil’s $57B Pharma Market: The IP, Patent, and Competitive Intelligence Playbook Read Post »
Navigating the Intellectual Property Minefield: A Strategic Guide to Mitigating Patent Litigation Risks in M&A Due Diligence
Why Pharma M&A Is Really a Patent Acquisition Business When AstraZeneca paid $39 billion for Alexion in 2021, it wasn’t
A Strategic Guide to Capitalizing on Patent Expiry, Generic Entry, and Product Reformulation
The patent cliff is measurable, foreseeable, and still consistently underestimated. Between 2025 and 2030, the U.S. pharmaceutical market will surrender
The $700B Generic Drug Margin Trap — And How PAT/QbD Gets You Out
A deep strategic analysis of Process Analytical Technology and Quality by Design as instruments of competitive differentiation, IP defense, cost
The $700B Generic Drug Margin Trap — And How PAT/QbD Gets You Out Read Post »
How Chemical Patent Non-Infringement Strategy Wins Drug Markets
The complete analytical guide for pharma IP teams, portfolio managers, and generic entrants: from claim construction and Markush deconstruction to
How Chemical Patent Non-Infringement Strategy Wins Drug Markets Read Post »
